
Joseph Rossano, MD, MPH, discusses the 56-week active-treatment period of the SCOUT-HCM trial, which demonstrated the sustainability of mavacamten’s effects.

Joseph Rossano, MD, MS, is the co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

Joseph Rossano, MD, MPH, discusses the 56-week active-treatment period of the SCOUT-HCM trial, which demonstrated the sustainability of mavacamten’s effects.

Joseph Rossano, MD, MS, discusses the SCOUT-HCM trial, mavacamten’s expanded indication, and what it means for pediatric oHCM.

Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten’s comparative superiority in reducing left ventricular outflow.